Morgan Stanley Zymeworks Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.43 $15.3 Million - $24.5 Million	3,299,737 Added 168.42%	5,258,975 $32.3 Million
Q2 2022 Oct 27, 2022	SELL	$4.82 - $7.7 $1.81 Million - $2.89 Million	-374,790 Reduced 16.06%	1,959,238 $10.4 Million
Q2 2022 Aug 15, 2022	SELL	$4.82 - $7.7 $1.81 Million - $2.89 Million	-374,790 Reduced 16.06%	1,959,238 $10.4 Million
Q1 2022 Oct 27, 2022	BUY	$6.0 - $16.98 $2.25 Million - $6.36 Million	374,790 Added 19.13%	2,334,028 $15.3 Million
Q1 2022 May 13, 2022	BUY	$6.0 - $16.98 $1.32 Million - $3.73 Million	219,456 Added 10.38%	2,334,028 $15.3 Million
Q4 2021 Feb 14, 2022	SELL	$15.19 - $29.33 $2.76 Million - $5.33 Million	-181,850 Reduced 7.92%	2,114,572 $34.7 Million
Q3 2021 Nov 15, 2021	BUY	$27.35 - $37.28 $62.8 Million - $85.6 Million	2,296,422 New	2,296,422 $66.7 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $882M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.